Matrimonial |  Properties |  Jobs |  Classifieds |  Ask Doctor |  Live TV |  Sponsored Greetings |  Astrology  |   Red Chillies |  Automobile |  Music |  Tribute

      Search in

Tuesday, July 09, 2013 11:20:18 AM (IST)  

Ranbaxy to pay $420,000 in US for selling sub-standard drugs

Washington, Jul 9 (IANS): Indian generic drug manufacturer Ranbaxy will pay Idaho state in northwestern US nearly $420,000 to settle civil and criminal complaints of selling drugs of inferior strength, purity or quality.

Idaho had joined several states and the US government in alleging that Ranbaxy products manufactured between April 2003 and September 2010 did not meet US Food and Drug Administration standards and caused Medicaid to pay fraudulent claims. Medicaid is a US health programme for families and individuals with low income and resources.

The alleged 26 sub-standard generic drugs were made at Ranbaxy's factories in Paonta Sahib and Dewas in India.

The company agreed to a $500 million settlement with the federal and state governments. About $266.7 million of that will go to Medicaid programmes that are jointly funded by federal and state taxes.

"Taxpayers expect their tax dollars to be used to pay for a legitimate service," Idaho Attorney General Lawrence Wasden said in a press release. "This settlement reflects our resolve to address losses to the Idaho Medicaid programme caused by individuals and companies."

Idaho's share of the settlement is $419,914. About half of that will go to Idaho Medicaid as restitution, and about half will go to Idaho's general fund.

The company also pleaded guilty to seven felony counts of violating the US Food, Drug and Cosmetic Act and agreed to pay $150 million in criminal fines and forfeitures.

Stay updated wherever you go with and Daijiworld 24X7 tv channel mobile apps.
CLICK HERE to download it for your device.
(available on Android and IOS)

Comments on this article
Jossey Saldanha, Mumbai
Tuesday, July 09, 2013


Bollu, Mangalore
Tuesday, July 09, 2013

For America whatever products from India is of sub-standard..
Earlier..they even banned our silk items..claiming not good to making demonstration..
Coconut earlier also banned saying it's not good for health..
Whatever items not available in there country is considered not so good.. To export any of items..cannot go beyond on it's limit due to quota system.
For them Junk food/Beverages is meant to be of good quality. Dual Policy..

For Ranbaxy it's not so big will dump stock in anyof third world..!!

Naveens, Mangalore
Tuesday, July 09, 2013

You need to read about Good Manufacturing Practices (CFR 210 and CFR 211) to understand the importance of quality drugs and their effectiveness. Also search for 483 Warning letters (this will explain why FDA fined a company).

RM, Dubai
Tuesday, July 09, 2013

Union Carbide was not made to pay for blunder they made in Bhopal. Now Indian Company is made to pay. Harming human life is wrong, but this should be implemented to all International companies too. Why Indian Govt. bend to these pressures.

rohan, mangalroe/oman
Tuesday, July 09, 2013

Ranbaxy has been producing drugs to Indian markets too, if this is the case with it, the Govt has to test all its products marketed in India. Sardar of Ranbaxy seems to be in a hurry to mint fast money..

Siva Avadani, Udupi/Dubai
Tuesday, July 09, 2013

This is America, no one is spared. In India who cares for its citizens. In addition authorities in India would have taken the bribe and settle the matter.

Print this Article
Email this article to your friend
Write your Comments
News Title Ranbaxy to pay $420,000 in US for selling sub-standard drugs
Your Name
Native Place / Place of Residence
Your E-mail
Your Comment
[Please limit your comments within 2000 characters]

You have characters left.
Disclaimer: Please write your correct name and email address. Kindly do not post any personal, abusive, defamatory, infringing, obscene, indecent, discriminatory or unlawful or similar comments. will not be responsible for any defamatory message posted under this article.

Please note that sending false messages to insult, defame, intimidate, mislead or deceive people or to intentionally cause public disorder is punishable under law. It is obligatory on Daijiworld to provide the IP address and other details of senders of such comments, to the authority concerned upon request.

Hence, sending offensive comments using daijiworld will be purely at your own risk, and in no way will be held responsible.
Security Validation
Enter the characters in the image above
Published by Daijiworld Media Pvt Ltd Mangalore
Editor-in-chief : Walter Nandalike

Corporate Office :
Daijiworld Residency,
Airport Road, Bondel Post,
Mangalore - 575 008
Karnataka India
Telephone : +91-824-2982023
City Office :
First Floor,
Divya Deepa Arcade,
Bendorewell, Kankanady,
Mangalore - 575 002
Karnataka India
Telephone : +91-824-4259372
e-mail   General enquiry:, News & Info :

Disclaimer | Privacy Policy | About Us
Copyright 2001 - 2016. All rights reserved.
Our Franchise Offices
Kishoo Enterprises,
3rd Floor, Mandavi Trade Centre,
Kadiyali, Udupi 576 102
Telephone : 0091-820-4295571
e-mail :
Daijiworld Middle East FZE
P.O.Box: 84772, Dubai, UAE
Tel: 971-50-6597629  Fax: 971-4-2639207
There has been a database error. Technical Support has already been notified. You will be informed when this issue is resolved. Thank you for your patience!